within Pharmacolibrary.Drugs.ATC.V;

model V03AF03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0034166666666666664,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.009,
    k12             = 515,
    k21             = 515
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AF03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Calcium folinate (leucovorin calcium) is a medication used to reduce the toxic effects of folic acid antagonists such as methotrexate. It is also used in combination with 5-fluorouracil in the treatment of colorectal cancer. Calcium folinate is approved and widely used today as a rescue agent in chemotherapy protocols.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>McGuire, BW, et al., &amp; Stokstad, EL (1988). Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. <i>Clinical pharmacy</i> 7(1) 52–58. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3257913/&quot;>https://pubmed.ncbi.nlm.nih.gov/3257913</a></p></li><li><p>Liu, Y, et al., &amp; Li, Y (2015). Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. <i>European journal of drug metabolism and pharmacokinetics</i> 40(4) 443–451. DOI:<a href=&quot;https://doi.org/10.1007/s13318-014-0222-9&quot;>10.1007/s13318-014-0222-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25173761/&quot;>https://pubmed.ncbi.nlm.nih.gov/25173761</a></p></li><li><p>Wellington, K, &amp; Goa, KL (2001). Oral tegafur/uracil. <i>Drugs &amp; aging</i> 18(12) 935–950. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200118120-00005&quot;>10.2165/00002512-200118120-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11888348/&quot;>https://pubmed.ncbi.nlm.nih.gov/11888348</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AF03;
